Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia

Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia - Comparative study of mode of administration of silodosin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002188

Enrollment

100

Registered

2009-08-01

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

Silodosin 4mg once daily Silodosin 2mg twice daily

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Man with benign prostatic hyperplasia who treated by tamsulosin or naftpidil,and to fill the following items 1.I-PSS total score:over 8 points 2.QOL score:over 4 points

Exclusion criteria

Exclusion criteria: 1.Men who treated by the medicin that has possibility to influence the urination function 2.prostatic cancer 3.Urinary tract infection 4.urolithiasis 5.hepatic dysfunction, renal dysfunction, cardiac disease 6.orthostatic hypotention 7.Any other clinically relevant laboratory abnormality as judged by the investigator

Design outcomes

Primary

Measure	Time frame
Change and change rate of I-PSS total score,subscore	—

Countries

Japan

Contacts

Public ContactKunitaro Sanuki

JR Tokyo General Hospital Urology

sanuki@jreast.co.jp03-3320-2200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026